A new study reveals a novel connection between aging of visceral adipose tissue and brain health. These findings are ...

If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...

Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...

Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...

Higher adherence to the Mediterranean diet reduced the risk of obesity-related cancers, but not in the way researchers ...

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

The NHS medical director has cautioned about the side effects of certain medications following the latest findings ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...